Lab Invest 2006, 86:687–696.PubMedCrossRef 42. Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, Anania FA: Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular

carcinoma cells. Cancer Res 2007, 67:2497–2507.PubMedCrossRef 43. Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, Steveling K, Reis H, Cicinnati Inhibitor Library research buy VR, Schmid KW, Baba HA: Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 2008, 48:83–90.PubMedCrossRef 44. Lou L, Ye W, Chen Y, Wu S, Jin L, He J, Tao X, Zhu J, Chen X, Deng A, Wang check details J: Ardipusilloside inhibits survival, invasion and metastasis of human hepatocellular carcinoma cells. Phytomedicine 2012, 19:603–608.PubMedCrossRef 45. Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, Cao LQ, Chen LZ, Tan HX, Li W, Bi J, Zhang LJ: Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol Res 2009, 39:177–186.PubMedCrossRef 46. Tang CH, Tsai CC: CCL2 increases MMP-9 expression and cell motility in human chondrosarcoma cells via the Ras/Raf/MEK/ERK/NF-kappaB signaling pathway. Biochem Pharmacol 2012, 83:335–344.PubMedCrossRef

47. Wang J, Lu Y, Wang J, Koch AE, Zhang J, Taichman RS: CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway. Cancer Res 2008, 68:10367–10376.PubMedCrossRef

48. Hsiang CY, Wu SL, Chen JC, Lo HY, Li CC, Chiang SY, Wu HC, Ho TY: Acetaldehyde induces matrix metalloproteinase-9 gene expression via nuclear factor-kappaB and activator protein 1 signaling pathways in human hepatocellular carcinoma cells: association with the invasive potential. Toxicol Lett 2007, 171:78–86.PubMedCrossRef 49. Li J, Lau GK, Chen L, Dong SS, Lan HY, Huang XR, Li Y, Luk JM, Yuan YF, Guan XY: Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced Temsirolimus concentration matrix metalloproteinases 2 and 9 expression. PloS one 2011, 6:e21816.PubMedCrossRef Competing interests The learn more Authors declared that they have no competing interests. Authors’ contributions JFC and ZGR conceived and designed the study, YHW, YYD, WMW, XYX performed the experiments and analyzed the data, YHW and YYD wrote the manuscript. ZMW, RXC contributed statistical analysis. JC, DMG supervised cell and animal experiment. All authors read and approved the final manuscript.”
“Introduction Primary breast cancer is one of the main public health problems worldwide. Over 1.3 million women are diagnosed annually with primary breast cancer and approximately 458,000 will die from the disease [1].

The significance of the survival difference was examined by the log-rank test. P < 0.05 was considered statistically significant. Statistical analyses were performed with the Statview software package (SAS Institute, Inc, Cary, NC). Results CLU was upregulated in chemoresistant ovarian cancer tissues In a pilot

experiment to check the relationship between CLU overXAV-939 expression and chemoresistance in clinical samples from ovarian cancer patients, we performed immunohistochemistry using CLU Ab. Table 1 summarized CLU expression in eight primary ovarian cancer specimens together with their recurrent matched tumors. Importantly, primary chemo-responsive tumors showed Kinase Inhibitor Library datasheet either very limited or moderate CLU expression while CLU expression decreased in the recurrent tumors from same patients after chemotherapy course (Figure 1A.1,.2, respectively). In contrast, primary tumor samples from chemo-resistant cancers showed either high or moderate CLU expression in the primary tumor, and CLU expression was still high or up-regulated in the recurrent tumors (Figure 1A.3,.4, respectively). Table 1 Clusterin expression pattern in the primary and recurrent ovarian cancers Case (patient’s age) Chemo-senitivity primary tumor Persistent/recurrent t. histology FIGO stage  

  CLU intensity CLU intensity     1 (57) responsive ++ + serous IIIc 2 (48) responsive Z IETD FMK ++ + serous IIIc 3 (48) resistant + ++ serous IV 4 (53) resistant + +++ serous IV 5 (59) resistant + +++ serous IV 6 (52) resistant ++ +++ serous IIIc 7 (51) resistant N ++ serous IV 8 (55) resistant +++ +++ serous IIIC N denotes negative staining,

(+) denote weak staining (++) denote moderate staining, while (+++) denotes strong staining. Figure 1 Immunohistochemical detetion of CLU in ovarian cancer tissue samples old A. Representative images from immunohistochemistry detection of CLU expression in primary tumor specimens from chemo-responsive tumor tissues (1). CLU staining is moderate or very low. Recurrent tumor from the same patient also showed extremely limited staining of CLU (2). CLU staining in the primary tumor from chemo-resistant tumor tissue (3) showed high CLU expression. Recurrent tumors from the same patients, however, showed high CLU expression after chemotherapy (4).B. Representative photos of immunohistochemical expression of CLU in 47 tissue samples of ovarian cancer. 1) high expression, 2) moderate expression, 3) low expression, and 4) negative expression. C. Kaplan-Meier survival curve according to CLU expression (1), stage (2) and histology (3). Survival of patients with high and moderate expression of CLU showed significantly poor survival than that of low and negative expression of CLU (p = 0.04).

Phys Rev Lett 2011, 106:220402.OSI-027 purchase CrossRef 6. Fu L, Kane CL: Superconducting proximity effect and click here Majorana fermions at the surface of a topological insulator . Phys Rev Lett 2008, 100:096407.CrossRef 7. Tanaka Y, Yokoyama

T, Nagaosa N: Manipulation of the Majorana fermion, Andreev reflection, and Josephson current on topological insulators . Phys Rev Lett 2009, 103:107002.CrossRef 8. Klinovaja J, Gangadharaiah S, Loss D: Electric-field-induced Majorana Fermions in Armchair Carbon Nanotubes . Phys Rev Lett 2012, 108:196804.CrossRef 9. Read N, Green D: Paired states of fermions in two dimensions with breaking of parity and time-reversal symmetries and the fractional quantum Hall effect . Phys Rev B 2000, 61:10267.CrossRef 10. Potter AC, Lee PA: Majorana end states in multiband microstructures with Rashba spin-orbit coupling . Phys Rev B 2011, 83:094525.CrossRef 11. Wong CLM, Liu J, Law KT, Lee PA: Majorana flat bands and unidirectional Majorana edge states in gapless topological superconductors . Phys Rev B 2013, 88:060504(R).CrossRef 12. Chamon C, Hou C-Y, Mudry C, Ryu S, Santos L: Masses and Majorana fermions

in graphene . Phys. Scr 2012, T146:014013.CrossRef 13. Lutchyn RM, Sau JD, Das SS: Majorana fermions and a topological phase transition in semiconductor-superconductor heterostructures Pifithrin-�� ic50 . Phys Rev Lett 2010, 105:077001.CrossRef 14. Oreg Y, Refael G, von Oppen F: Helical liquids and Majorana bound states

in quantum wires . Phys Rev Lett 2010, 105:177002.CrossRef 15. Mourik V, Zuo K, Frolov SM, Plissard SR, Bakkers EPAM, Kouwenhoven LP: Signatures of Majorana fermions in hybrid superconductorsemiconductor nanowire devices . Science 2012, 336:1003.CrossRef 16. Deng MT, Yu CL, Huang GY, Larsson M, Caroff P, Xu HQ: Anomalous zero-bias conductance peak in a Nb-InSb Nanowire-Nb hybrid device . Nano Lett 2012, 12:6414.CrossRef 17. Das A, Ronen Y, Most Y, Oreg Y, Heiblum M, Shtrikman H: Zero-bias peaks and splitting in an Al-InAs nanowire topological superconductor as a signature of Majorana fermions . Nat Phys 2012, 8:887.CrossRef 18. Lee EJH, Jiang X, Aguado R, Katsaros G, Lieber CM, De FS: Zero-bias anomaly in a nanowire quantum dot coupled to superconductors . Phys Rev Lett 2012, 109:186802.CrossRef 19. Churchill HOH, Fatemi V, Grove-Rasmussen 3-mercaptopyruvate sulfurtransferase K, Deng MT, Caroff P, Xu HQ, Marcus CM: Superconductor-nanowire devices from tunneling to the multichannel regime: zero-bias oscillations and magnetoconductance crossover . Phys Rev B 2013, 87:241401.CrossRef 20. Rokhinson LP, Liu XY, Furdyna JK: The fractional a. c. Josephson effect in a semiconductor-superconductor nanowire as a signature of Majorana particles . Nat Phys 2012, 8:795.CrossRef 21. Law KT, Lee PA, Ng TK: Majorana fermion induced resonant Andreev reflection . Phys Rev Lett 2009, 103:237001.CrossRef 22.

The chemical structure of TPGS-b-(PCL-ran-PGA) copolymer is shown in Figure 2A. In order to further confirm the formation AZD1152 research buy of the random copolymer, the 1H NMR spectrum is recorded and is shown in Figure 2B. The peak at

3.65 ppm (Figure 2, peak e) could be attributed to the -CH2 protons of the PEO part of TPGS [2, 41]. The lower signals in the aliphatic zone belong to various moieties of vitamin E tails [2, 41]. Peaks at 1.39 (h), 1.67 (g), 2.31 to 2.44 (f), and 4.06 ppm (d) are assigned to methylene protons in PCL units, respectively [2, 41]. The difference between the two peaks at 4.06 (c) and 4.16 ppm (b) which indicated that two kinds of copolymers would be obtained was reasonable (shown in Figure 2). Furthermore, it was from the appearance of the two different peaks that we could conclude that both GA ICG-001 and CL monomers had copolymerized with TPGS monomers. The characteristic signal at 4.62 to 4.82 ppm (a) exists, which is attributed to the

methylene (CH2) protons of the PGA units [41]. The molecular selleck chemical weight of the TPGS-b-(PCL-ran-PGA) copolymer was calculated by the use of the ratio between the peak areas at 4.06, 4.62 to 4.82, and 3.65 ppm. The Mn of the TPGS-b-(PCL-ran-PGA) copolymer was estimated to be 23,852. The Mn calculated from the gel permeation chromatograph was 25,811. It seemed that the molecular weight measured from NMR and GPC can confirm each other. Figure 1 FT-IR spectra of TPGS and TPGS- b -(PCL- ran -PGA) copolymer. Figure 2 Chemical structure (A) and typical 1 H NMR spectra (B) of TPGS- b -(PCL- ran -PGA) copolymer. Construction and expression of pShuttle2-TRAIL and pShuttle2-endostatin Recombinant plasmids pShuttle2-TRAIL and pShuttle2-endostatin were verified by enzyme digestion and DNA sequencing. Protein expression of TRAIL and endostatin was analyzed not by Western blot using cell lysate after transfection of HeLa cells using PEI (Figure 3). These results showed that pShuttle2-TRAIL and pShuttle2-endostatin were successfully constructed

and expressed in HeLa cells. Figure 3 Western blot analysis of recombined pShuttle2-endostatin and pShuttle2-TRAIL expression in 293 T cells. Control: 293 T cells transfected by pShuttle2. rE: 293 T cells transfected by pShuttle2-endostatin. rT: 293 T cells transfected by pShuttle2-TRAIL. Characterization of nanoparticles The effect of PEI modification on particle size was determined by dynamic light scattering (DLS; Table 1). The average hydrodynamic diameter of the polyplexed PEI/pDNA nanoparticles (CNP) was 83 nm, whereas the diameters of the unmodified TPGS-b-(PCL-ran-PGA) nanoparticles (DNP) and PEI-modified TPGS-b-(PCL-ran-PGA) nanoparticles (HNP) were approximately 215 and approximately 273 nm, respectively (Figure 4A). In addition, the surface charge (zeta potential) of the nanoparticles was determined by laser Doppler anemometry (Zetasizer Nano ZS90, Malvern Instruments, Malvern, UK; Table 1 and Figure 4B).

Breast Cancer Res Treat 2005,93(3):255–260.PubMed 132. Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, Costa A, Winer EP, Cardoso F: International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured? J Natl Cancer Inst 2010,102(7):456–463.PubMed 133. Ogawa Y, Ikeda K, Izumi T, Okuma S, Ichiki M, Ikeya T, Morimoto J, Nishiguchi Y, Ikehara T: First indicators of relapse in breast cancer: evaluation of the follow-up program at our hospital. Int

J Clin Oncol 2012,18(3):447–53.PubMed 134. Barni S, Venturini M, Molino A, Donadio PLX3397 price M, Rizzoli S, Maiello E, Gori S: Importance of adherence to guidelines in breast cancer clinical practice. The Italian experience (AIOM). Tumori 2011,97(5):559–563.PubMed 135. Donnelly P, Hiller L, Bathers S, Bowden S, Coleman R: Questioning specialists’ attitudes to breast cancer follow-up in primary care. Ann Oncol 2007,18(9):1467–1476.PubMed 136. Montgomery DA, Krupa K, Cooke TG: Alternative methods of follow up in breast cancer: a systematic review of the literature. Br J Cancer 2007,96(11):1625–1632.PubMed 137. Geurts SM, De Vegt F, Siesling

S, Flobbe K, Aben KK, Van Der Heiden Van Der Loo M, Verbeek AL, Van Dijck click here JA, Tjan Heijnen VC: Pattern of follow-up care and early relapse detection in breast cancer patients. Breast Cancer Res Treat 2012,136(3):859–868.PubMed 138. Dewar JA, Kerr GR: Value of routine follow up of women treated for early carcinoma of the breast. Br Med J (Clin Res Ed) 1985,291(6507):1464–1467. 139. Pandya KJ, McFadden ET, Kalish LA, Tormey DC, Taylor SG, Falkson G: A retrospective study of earliest indicators of recurrence in patients on Eastern Cooperative Oncology Group adjuvant chemotherapy trials for breast cancer. A preliminary report. Cancer 1985,55(1):202–205.PubMed 140. Schapira DV, RG7420 cost Urban N: A minimalist policy for breast cancer surveillance. JAMA 1991,265(3):380–382.PubMed 141. Zwaveling A, Albers GH, Felthuis W, Hermans J: An evaluation of routine follow-up for detection of breast cancer recurrences. J Surg Oncol 1987,34(3):194–197.PubMed 142. Smith TJ, Davidson NE, Schapira DV, Grunfeld E, Muss HB, Vogel VG 3rd, Somerfield MR: American Society

of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 1999,17(3):1080–1082.PubMed 143. Bonomi M, Pilotto S, Milella M, Massari F, Cingarlini S, Brunelli M, Chilosi M, Tortora G, Bria E: Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. J Exp Clin Cancer Res 2011,30(1):115–123.PubMed Competing interests The authors have no potential conflicts of interest to declare. Authors’ contributions IS supervised the data collection, I-BET-762 clinical trial performed the statistical analyses and revised the manuscript; AG, MDT and GC performed literature search and data extraction; NT and TG wrote the manuscript; PV and SI critically revised the manuscript; CN conceived the study and critically revised the manuscript.

Ellington JK, Harris M, Hudson MC, Vishin S, Webb LX, Sherertz

R: Intracellular Staphylococcus aureus and antibiotic resistance: Implications for treatment of staphylococcal osteomyelitis. J Orthop Res 2006, 24(1):87–93.PubMedCrossRef 18. Armstead AL, Li BY: Nanomedicine as an emerging approach against intracellular pathogens. Int J Nanomedicine 2011, 6:3281–3293.PubMedPubMedCentral 19. Favus MJ, American Society for Bone and Mineral Research: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 6th edition. Washington, DC: American Society for Bone and Mineral Research; 2006. 20. Bost KL, Ramp WK, Nicholson NC, Bento JL, Marriott I, Hudson MC: Staphylococcus aureus infection of mouse or human osteoblasts induces high levels of interleukin-6 and interleukin-12 production. J Infect Dis 1999, 180(6):1912–1920.PubMedCrossRef 21. Wright KM, Friedland Lazertinib JS: Differential regulation of chemokine secretion in tuberculous and staphylococcal osteomyelitis. J Bone Miner Res 2002, 17(9):1680–1690.PubMedCrossRef 22. Tucker KA, Reilly SS, Leslie CS, Hudson MC: Intracellular Staphylococcus aureus induces apoptosis in mouse osteoblasts. FEMS Microbiol

Lett 2000, 186(2):151–156.PubMedCrossRef 23. Ellington JK, Reilly SS, Ramp WK, Smeltzer MS, Kellam JF, Hudson MC: Mechanisms of Staphylococcus aureus invasion of cultured osteoblasts. Microb Pathog 1999, 26(6):317–323.PubMedCrossRef 24. Allardyce Foretinib ic50 RA, Wang Y, Rogers GR, Gillespia WJ, Doyle JS: The destruction of bone by neutrophils. Chin Med J 1995, 108(9):708–709.PubMed 25. Amer AO, Swanson MS: A phagosome of one’s own: a microbial guide to life in the Amobarbital macrophage. Curr Opin Microbiol 2002, 5(1):56–61.PubMedCrossRef 26. Staali

L, Bauer S, Morgelin M, Bjorck L, Tapper H: Streptococcus pyogenes bacteria modulate membrane traffic in human neutrophils and selectively inhibit azurophilic granule fusion with phagosomes. Cell Microbiol 2006, 8(4):690–703.PubMedCrossRef 27. Haslett C, Savill JS, Whyte MKB, Stern M, Dransfield I, Meagher LC: Granulocyte apoptosis and the control of inflammation. Philos T Roy Soc B 1994, 345(1313):327–333.CrossRef 28. Petti CA, Fowler VG: Staphylococcus aureus bacteremia and endocarditis. Infect Dis Clin N Am 2002, 16(2):413.CrossRef 29. Haslinger-Loffler B, Kahl BC, Grundmeier M, Strangfeld K, Veliparib mouse Wagner B, Fischer U, Cheung AL, Peters G, Schulze-Osthoff K, Sinha B: Multiple virulence factors are required for Staphylococcus aureus-induced apoptosis in endothelial cells. Cell Microbiol 2005, 7(8):1087–1097.PubMedCrossRef 30. Haslinger B, Strangfeld K, Peters G, Schulze-Osthoff K, Sinha B: Staphylococcus aureus alpha-toxin induces apoptosis in peripheral blood mononuclear cells: role of endogenous tumour necrosis factor-alpha and the mitochondrial death pathway. Cell Microbiol 2003, 5(10):729–741.PubMedCrossRef 31.

8% agarose gel and a QIAquick Gel Extraction Kit (Cat# 28704, Qiagen) per the manufacturer’s instructions. Defined DNA community composition Two defined DNA mixture were created using 10 different plasmids, each containing a near full length 16S rDNA amplicon, obtained using primers BSF8 and BSR1541. One mixture had an equal amount of each plasmid and one was staggered to contain different proportions of each clone. The strains and proportions on the Staggered mix are: Clostridium dificile (ATCC#: BAA-1382) – 39.99%, Bacteroides fragilis (ATCC#: 25285) – 32.01%, Streptococcus pneumoniae (ATCC#: BAA_334)

– 4.92%, Desulfovibrio vulgaris (ATCC#: 29579) – 1.95%, Campylobacter jejunii (ATCC#: 700819) – 2.03%, Rhizobium vitis (ATCC#: BAA_846) – 2.00%, Lactobacillus Selleckchem PND-1186 delbruekii (ATCC#: BAA-365) – 5.06%, Escherichia coli HB101 – 2.01%, Treponema sp. (macaque stool clone) – 7.97%, and Nitrosomonas sp. (environmental clone) – 2.04%. Clones were made using the Topo-XL kit (Cat# K4700-20, Invitrogen, Carlsbad, CA). Two polymerases were tested for the Staggered mix, AmpliTaq (as used for stool DNA samples) and GreenTaq (Promega, Madison,

WI) as per manufacturer instructions. The PCR cycling conditions were the same as described for the stool sample DNA. 454/Roche sequencing methods Purified amplicon DNAs were quantified using Quant-iT PicoGreen kit (cat# P7589, Invitrogen, Carlsbad, CA) and pooled for pyrosequencing. Pyrosequencing using the 454/Roche GS FLX chemistry was carried out according to the manufacturer’s instructions. Pyrosequencing using the Titanium MK-8931 method was carried out using the Titanium genomic kit. Primers for PCR amplification MLN2238 datasheet of rDNA gene segments are in Additional File 3. The rDNA region amplified with V1-V2 primers used for FLX sequencing is contained within

the regions amplified with the V1-V3 primers used for Titanium sequencing. Pyrosequence reads were uploaded into QIIME and processed as described (Caporaso et al., 2010). Briefly, QIIME accepts as input bar coded 16S rRNA gene sequences, classifies them using the RDP classifier [23], aligns them using Pynast [31], constructs phylogenetic trees using FastTree2, calculates UniFrac distances, and generates data summaries of the proportions of taxa present and PCoA plots based on UniFrac distances. We used 97% OTUs in the analysis. For the RDP very classifier, we required >50% confidence for all calls. Accession numbers for sequences determined here are in Additional File 5. Statistical methods Clinical characteristics were compared as median, range, counts and percentages. For analysis in Figures 1 and 2, no corrections for multiple comparisons were applied. UniFrac [33, 34, 41] was used to generate distances between all pairs of communities; both weighted and unweighted UniFrac were used in the analyses. Statistical analysis was carried out by comparing distances within groups to distances between groups.

Editorial support for the final version of this article, comprising of language editing, content checking, formatting, and referencing was provided by Sophie Rushton-Smith, Ph.D. Dr Boonen is senior clinical investigator of the

Fund for Scientific Research, Flanders, Belgium (F.W.O.-Vlaanderen) and holder of the Leuven University Chair in Metabolic Bone Diseases. Funding GLOW is sponsored by a grant from The Alliance for Better Bone Health (Procter & Gamble Pharmaceuticals GS-1101 mw and sanofi-aventis). Conflicts of interest Ethel S Siris—consulting fees: Amgen, Lilly, Merck, Procter & Gamble, sanofi-aventis, Novartis. Stephen Gehlbach—research and salary support: The Alliance for Better Bone Health (Procter & Gamble Pharmaceuticals, sanofi-aventis). Jonathan D Adachi—research NSC 683864 purchase and salary support: Amgen, Astra Zeneca, Eli Lilly, GlaxoSmithKline, Merck, selleck chemicals llc Novartis, Nycomed, Pfizer, Procter & Gamble, Roche, sanofi-aventis, Servier, Wyeth, Bristol-Myers Squibb; clinical trials: Amgen, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, Procter & Gamble, Roche, sanofi-aventis, Wyeth, Bristol-Myers Squibb. Steven Boonen—research grants: Amgen, Eli Lilly, Novartis, Pfizer, Procter & Gamble, sanofi-aventis, Roche, GlaxoSmithKline; Speakers’ bureau:

Amgen, Eli Lilly, Merck, Novartis, Procter & Gamble, sanofi-aventis, Servier; honoraria: Amgen, Eli Lilly, Merck, Novartis, Procter & Gamble, sanofi-aventis, Servier; consultant/advisory board: Amgen, Eli Lilly, Merck, Novartis, Procter & Gamble, sanofi-aventis, Servier. Roland Chapurlat—research grants: French Ministry of Health, Servier, Lilly, Procter & Gamble; honoraria from Servier, Novartis, Lilly, Roche, sanofi-aventis, Maxence Pharma; consultant/advisory board: Servier, Nycomed, Novartis, Maxence Pharma. Juliet Compston—consultancy: Servier, Shire, Nycomed, Novartis, Amgen, Procter & Gamble, Wyeth, Pfizer, The Alliance IMP dehydrogenase for Better Bone Health, Roche, GlaxoSmithKline; speaking engagements (with reimbursement, travel and accommodation): Servier, Procter & Gamble, Eli

Lilly; research grants: Servier R&D, Procter & Gamble. Cyrus Cooper—consultancy and lecturing: Amgen, The Alliance for Better Bone Health, Eli Lily, Merck Sharp and Dohme, Servier, Novartis, Roche-GSK. Pierre Delmas: None. Adolfo Díez-Pérez—honoraria: Novartis, Eli Lilly, Amgen, Procter & Gamble, Roche; Expert witness for Merck—consultant/advisory board: Novartis, Eli Lilly, Amgen, Procter & Gamble; research and salary support: Novartis, Eli Lilly, Amgen, Procter & Gamble, Roche. Frederick H Hooven—research and salary support: The Alliance for Better Bone Health (Procter & Gamble Pharmaceuticals, sanofi-aventis). Andrea LaCroix—research and salary support: The Alliance for Better Bone Health (Procter & Gamble Pharmaceuticals and sanofi-aventis).